Bilski's Broad Sweep: Federal Circuit Says Vaccination Schedule Analysis Is Patentable
This article was originally published in The Pink Sheet Daily
Executive Summary
In Classen v. Biogen Idec the court rules that patents on a method of determining the administration schedule of vaccines are patent-eligible; the case applies the Supreme Court's Bilski decision on process patents to the biotech field.
You may also be interested in...
Hatch-Waxman Safe Harbor Ruling Wrong In GSK Case, Solicitor General Says, But Should Not Be Reviewed
Supreme Court should not take up GlaxoSmithKline v. Classen given the Federal Circuit’s subsequent decision in Momenta v. Amphastar, the Solicitor General argues; Momenta plans to seek review of its case.
Hatch-Waxman “Safe Harbor” Could Face Two-Front Battle In Supreme Court
Momenta plans to seek high court review of the scope of the “Bolar Amendment” in an enoxaparin patent dispute; activity in a second “safe harbor” case at the Supreme Court is expected to resume now that the appeals court proceedings in Momenta v. Amphastar have concluded.
Hatch-Waxman “Safe Harbor” Ruling Threatens Compound Patents, Momenta Says
Enoxaparin marketing partners Momenta and Sandoz seek rehearing en banc of an appellate panel’s decision that broadly interpreted the scope of the so-called “Bolar Amendment.” Amphastar and Watson, whom the panel said were protected from patent infringement claims, oppose the request.